Profile data is unavailable for this security.
About the company
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
- Revenue in JPY (TTM)104.51bn
- Net income in JPY4.53bn
- Incorporated1945
- Employees1.52k
- LocationMochida Pharmaceutical Co Ltd1-7, YotsuyaSHINJUKU-KU 160-8515JapanJPN
- Phone+81 333587211
- Fax+81 333587887
- Websitehttps://www.mochida.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ASKA Pharmaceutical Holdings Co Ltd | 63.57bn | 5.98bn | 62.41bn | 762.00 | 9.68 | 0.9023 | 7.49 | 0.9818 | 210.94 | 210.94 | 2,243.73 | 2,263.17 | 0.7056 | 1.64 | 3.86 | 83,419,940.00 | 6.63 | 4.63 | 8.44 | 5.87 | 49.38 | 46.94 | 9.40 | 6.76 | 1.71 | -- | 0.1064 | 14.86 | 3.94 | 6.12 | 78.03 | 34.04 | -37.89 | 23.36 |
Katakura Industries Co., Ltd. | 38.12bn | 2.89bn | 70.18bn | 1.04k | 22.67 | 0.8455 | 12.17 | 1.84 | 87.92 | 87.92 | 1,158.05 | 2,357.16 | 0.2725 | 1.99 | 5.37 | 36,650,960.00 | 2.17 | 2.35 | 2.79 | 3.34 | 38.62 | 37.75 | 7.97 | 8.32 | 2.56 | -- | 0.1026 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
JCR Pharmaceuticals Co Ltd | 35.26bn | -437.00m | 82.74bn | 934.00 | -- | 1.41 | 26.47 | 2.35 | -3.49 | -3.49 | 281.91 | 451.84 | 0.338 | 0.4791 | 2.15 | 37,747,320.00 | -0.3864 | 8.66 | -0.5681 | 13.46 | 71.44 | 74.51 | -1.14 | 18.24 | 0.9827 | -0.3874 | 0.3325 | 30.60 | 24.83 | 13.11 | 46.00 | 8.19 | 18.54 | 21.67 |
Kyorin Pharmaceutical Co Ltd | 119.73bn | 4.82bn | 94.78bn | 2.04k | 17.50 | 0.6482 | 10.26 | 0.7916 | 83.83 | 83.83 | 2,084.19 | 2,263.35 | 0.6745 | 1.21 | 3.18 | 58,635,650.00 | 2.71 | 3.05 | 3.36 | 3.79 | 42.87 | 47.11 | 4.02 | 4.76 | 1.74 | -- | 0.1593 | 67.74 | 5.53 | 1.02 | 12.68 | -4.98 | 7.41 | -7.06 |
Nxera Pharma Co Ltd | 29.28bn | -3.71bn | 100.69bn | 350.00 | -- | 1.49 | 399.57 | 3.44 | -41.70 | -41.70 | 332.11 | 753.72 | 0.194 | 2.57 | 6.61 | 83,642,860.00 | -2.46 | -0.6588 | -2.76 | -0.7036 | 75.27 | 89.83 | -12.68 | -4.46 | 3.90 | -6.02 | 0.5060 | -- | -18.00 | -- | -1,982.98 | -- | -- | -- |
Zeria Pharmaceutical Co Ltd | 81.47bn | 8.40bn | 117.71bn | 1.78k | 11.63 | 1.11 | 7.21 | 1.44 | 190.47 | 190.47 | 1,848.22 | 2,002.47 | 0.5316 | 1.50 | 3.60 | 45,846,530.00 | 5.49 | 3.89 | 8.46 | 6.28 | 72.99 | 71.93 | 10.33 | 7.57 | 0.9178 | -- | 0.3244 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
Mochida Pharmaceutical Co Ltd | 104.51bn | 4.53bn | 122.15bn | 1.52k | 25.52 | 0.8952 | 16.44 | 1.17 | 127.75 | 127.75 | 2,945.16 | 3,641.81 | 0.6639 | 1.80 | 3.42 | 68,662,940.00 | 2.88 | 4.37 | 3.41 | 5.31 | 49.61 | 52.47 | 4.34 | 6.71 | 3.50 | -- | 0.00 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
Torii Pharmaceutical Co Ltd | 58.84bn | 5.28bn | 136.94bn | 583.00 | 25.33 | 1.11 | 24.04 | 2.33 | 187.71 | 187.71 | 2,093.33 | 4,271.84 | 0.4411 | 2.74 | 2.30 | 100,924,500.00 | 3.96 | 6.52 | 4.39 | 7.35 | 44.46 | 49.55 | 8.97 | 17.98 | 5.19 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
Towa Pharmaceutical Co Ltd | 243.94bn | 15.78bn | 145.64bn | 4.59k | 8.82 | 0.8747 | 4.21 | 0.597 | 320.50 | 320.50 | 4,956.02 | 3,232.16 | 0.5838 | 1.52 | 3.93 | 53,169,570.00 | 3.78 | 4.21 | 4.56 | 5.63 | 36.10 | 39.23 | 6.47 | 7.23 | 1.63 | -- | 0.581 | 21.01 | 9.13 | 16.74 | 634.80 | 3.72 | 28.20 | 10.86 |
Kissei Pharmaceutical Co Ltd | 81.07bn | 10.73bn | 182.70bn | 1.78k | 15.33 | 0.7456 | 11.96 | 2.25 | 241.71 | 241.71 | 1,825.83 | 4,969.03 | 0.3294 | 1.60 | 2.98 | 45,568,860.00 | 4.38 | 3.61 | 4.75 | 3.90 | 49.88 | 49.47 | 13.31 | 12.69 | 4.15 | -- | 0.0057 | 34.87 | 11.98 | 0.8919 | 6.00 | 15.28 | 6.58 | 10.40 |
Data as of Nov 21 2024. Currency figures normalised to Mochida Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
Holder | Shares | % Held |
---|---|---|
Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 771.40k | 2.06% |
The Vanguard Group, Inc.as of 06 Nov 2024 | 770.82k | 2.06% |
Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 368.30k | 0.98% |
Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 347.30k | 0.93% |
BlackRock Fund Advisorsas of 07 Nov 2024 | 317.60k | 0.85% |
Norges Bank Investment Managementas of 30 Jun 2024 | 205.76k | 0.55% |
Dimensional Fund Advisors LPas of 07 Nov 2024 | 196.00k | 0.52% |
Mitsubishi UFJ Asset Management Co., Ltd.as of 22 Jul 2024 | 139.20k | 0.37% |
Charles Schwab Investment Management, Inc.as of 07 Nov 2024 | 99.75k | 0.27% |
BlackRock Advisors (UK) Ltd.as of 07 Nov 2024 | 61.50k | 0.16% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.